Adjuvant abemaciclib for high-risk breast cancer: the story continues
- PMID: 34815015
- DOI: 10.1016/j.annonc.2021.10.214
Adjuvant abemaciclib for high-risk breast cancer: the story continues
Conflict of interest statement
Disclosure LS reports consulting fees from Novartis, Puma, Lumicell, and Avrobio. AM reports consultancy to Veracyte with no financial or other compensation. AB reports consulting/advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/Astra Zeneca, Puma, Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Diiachi Pharma/Astra Zeneca. TF reports institutional grants from Roche and Pfizer and personal fees from Affibody, Novartis, Pfizer, Roche, Exact Sciences, Veracyte and UpToDate.
Comment on
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical